126 related articles for article (PubMed ID: 25144413)
1. Metabolic effect and receptor signalling profile of a non-metabolisable insulin glargine analogue.
Werner U; Korn M; Schmidt R; Wendrich TM; Tennagels N
Arch Physiol Biochem; 2014 Oct; 120(4):158-65. PubMed ID: 25144413
[TBL] [Abstract][Full Text] [Related]
2. Differences in metabolic and mitogenic signallingof insulin glargine and AspB10 human insulin in rats [corrected].
Tennagels N; Welte S; Hofmann M; Brenk P; Schmidt R; Werner U
Diabetologia; 2013 Aug; 56(8):1826-34. PubMed ID: 23653049
[TBL] [Abstract][Full Text] [Related]
3. Concentrations of insulin glargine and its metabolites during long-term insulin therapy in type 2 diabetic patients and comparison of effects of insulin glargine, its metabolites, IGF-I, and human insulin on insulin and igf-I receptor signaling.
Varewijck AJ; Yki-Järvinen H; Schmidt R; Tennagels N; Janssen JA
Diabetes; 2013 Jul; 62(7):2539-44. PubMed ID: 23569175
[TBL] [Abstract][Full Text] [Related]
4. Long-acting insulin analogues elicit atypical signalling events mediated by the insulin receptor and insulin-like growth factor-I receptor.
Yehezkel E; Weinstein D; Simon M; Sarfstein R; Laron Z; Werner H
Diabetologia; 2010 Dec; 53(12):2667-75. PubMed ID: 20835859
[TBL] [Abstract][Full Text] [Related]
5. Effect of the long-acting insulin analogues glargine and degludec on cardiomyocyte cell signalling and function.
Hartmann T; Overhagen S; Ouwens DM; Raschke S; Wohlfart P; Tennagels N; Wronkowitz N; Eckel J
Cardiovasc Diabetol; 2016 Jul; 15():96. PubMed ID: 27422524
[TBL] [Abstract][Full Text] [Related]
6. Effect of insulin analogues on insulin/IGF1 hybrid receptors: increased activation by glargine but not by its metabolites M1 and M2.
Pierre-Eugene C; Pagesy P; Nguyen TT; Neuillé M; Tschank G; Tennagels N; Hampe C; Issad T
PLoS One; 2012; 7(7):e41992. PubMed ID: 22848683
[TBL] [Abstract][Full Text] [Related]
7. In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites.
Sommerfeld MR; Müller G; Tschank G; Seipke G; Habermann P; Kurrle R; Tennagels N
PLoS One; 2010 Mar; 5(3):e9540. PubMed ID: 20209060
[TBL] [Abstract][Full Text] [Related]
8. Classifying the adverse mitogenic mode of action of insulin analogues using a novel mechanism-based genetically engineered human breast cancer cell panel.
ter Braak B; Siezen CL; Kannegieter N; Koedoot E; van de Water B; van der Laan JW
Arch Toxicol; 2014 Apr; 88(4):953-66. PubMed ID: 24464500
[TBL] [Abstract][Full Text] [Related]
9. The metabolic and mitogenic properties of basal insulin analogues.
Tennagels N; Werner U
Arch Physiol Biochem; 2013 Feb; 119(1):1-14. PubMed ID: 23373726
[TBL] [Abstract][Full Text] [Related]
10. Equipotency of insulin glargine 300 and 100 U/mL with intravenous dosing but differential bioavailability with subcutaneous dosing in dogs.
Werner U; Tennagels N; Fanelli CG; Bolli GB
Diabetes Obes Metab; 2021 Jan; 23(1):166-174. PubMed ID: 33001554
[TBL] [Abstract][Full Text] [Related]
11. Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml.
Steinstraesser A; Schmidt R; Bergmann K; Dahmen R; Becker RH
Diabetes Obes Metab; 2014 Sep; 16(9):873-6. PubMed ID: 24571126
[TBL] [Abstract][Full Text] [Related]
12. Molecular characterisation of long-acting insulin analogues in comparison with human insulin, IGF-1 and insulin X10.
Hansen BF; Glendorf T; Hegelund AC; Lundby A; Lützen A; Slaaby R; Stidsen CE
PLoS One; 2012; 7(5):e34274. PubMed ID: 22590494
[TBL] [Abstract][Full Text] [Related]
13. Different impacts of acylated and non-acylated long-acting insulin analogs on neural functions in vitro and in vivo.
Tsuneki H; Yoshida H; Endo K; Mori N; Hosoh S; Tsuda M; Wada T; Sasaoka T
Diabetes Res Clin Pract; 2017 Jul; 129():62-72. PubMed ID: 28511140
[TBL] [Abstract][Full Text] [Related]
14. Non-metabolisable insulin glargine does not promote breast cancer growth in a mouse model of type 2 diabetes.
Gallagher EJ; Zelenko Z; Tobin-Hess A; Werner U; Tennagels N; LeRoith D
Diabetologia; 2016 Sep; 59(9):2018-25. PubMed ID: 27241182
[TBL] [Abstract][Full Text] [Related]
15. Glargine metabolism over 24 h following its subcutaneous injection in patients with type 2 diabetes mellitus: a dose-response study.
Lucidi P; Porcellati F; Candeloro P; Cioli P; Andreoli AM; Marzotti S; Schmidt R; Bolli GB; Fanelli CG
Nutr Metab Cardiovasc Dis; 2014 Jul; 24(7):709-16. PubMed ID: 24702815
[TBL] [Abstract][Full Text] [Related]
16.
Wronkowitz N; Hartmann T; Görgens SW; Dietze-Schroeder D; Indrakusuma I; Choi IY; Park SH; Lee YM; Kwon SC; Kang Y; Hompesch M; Eckel J
Diabetes Obes Metab; 2017 Dec; 19(12):1722-1731. PubMed ID: 28497570
[TBL] [Abstract][Full Text] [Related]
17. Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling.
Sciacca L; Cassarino MF; Genua M; Pandini G; Le Moli R; Squatrito S; Vigneri R
Diabetologia; 2010 Aug; 53(8):1743-53. PubMed ID: 20424816
[TBL] [Abstract][Full Text] [Related]
18. IGF-1 receptor signalling determines the mitogenic potency of insulin analogues in human smooth muscle cells and fibroblasts.
Eckardt K; May C; Koenen M; Eckel J
Diabetologia; 2007 Dec; 50(12):2534-43. PubMed ID: 17898992
[TBL] [Abstract][Full Text] [Related]
19. New insulin glargine 300 Units · mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units · mL-1.
Becker RH; Dahmen R; Bergmann K; Lehmann A; Jax T; Heise T
Diabetes Care; 2015 Apr; 38(4):637-43. PubMed ID: 25150159
[TBL] [Abstract][Full Text] [Related]
20. Effects of the long-acting insulin analog insulin glargine on cultured human skeletal muscle cells: comparisons to insulin and IGF-I.
Ciaraldi TP; Carter L; Seipke G; Mudaliar S; Henry RR
J Clin Endocrinol Metab; 2001 Dec; 86(12):5838-47. PubMed ID: 11739448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
